Alzheimer’s Disease: Opportunity Analyses – Beyond Bapi

July 2012 | 15 pages | ID: A8CC599D3B7EN
MP Advisors

Contents

1. UNMET NEED

1.1 Failures have not become the Pillars of Success
1.2 Safety is most critical for Approval

2. PURSUING MULTIPLE TARGETS- PIPELINE

3. MILESTONESTHR OUGH201 2-2015

4. DISEASE OVERVIEW AND DIAGNOSIS

5. CURRENT TREATMENT PARADIGM

5.1 Targeting of Aβ is Under Fire!

6. TREATMENT APPROACHES AND CLINICAL DATA:

6.1 Immunotherapy
  6.1.1 JNJ/PFE’s Bapineuzumab
  6.1.2 LLY’s Solanezumab
  6.1.3 Baxter’s Gammagard
  6.1.4 Roche/ MorphoSys’ Gantenerumab
  6.1.5 Bristol-Myers Squibb’s BMS-708163
  6.1.6 AstraZeneca/ Targacept’s AZD3480/ AZD1446
  6.1.7 Novartis/ Cytos Biotech’s CAD-106
  6.1.8 GSK/ Affiris’ AD02
6.2 Combination Therapies
  6.2.1 Medivation/ PFE’s Dimebon
  6.2.2 PFE/ ELN/ JNJ’s PF-05236806
6.3 Anti-Oxidation / Anti-Aggregation
  6.3.1 TauRx’s Rember/LMT
  6.3.2 Prana’s PBT2
  6.3.3 Elan/ Transition Therapeutics’ ELND005
6.4 Serotonin Modulators
  6.4.1 GSK’s SB-742457
  6.4.2 H. Lundbeck’s Lu AE58054
  6.4.3 Nanotherapeutics’ PRX-3140
  6.4.4 RaQualia Pharma’s RQ-00000009
  6.4.5 Challenges with 5-HT4
6.5 Others
  6.5.1 GSK’s GSK189254 (H3 inverse agonist)
  6.5.2 EnVivo Pharma’s EVP-6124 (Nicotinic A7 Agonist)
  6.5.3 Ceregene’s CERE-110 (NGF gene therapy)